Q1 2025 Earnings Call Transcript May 9, 2025 Kymera Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.82, expectations were $-0.92. Justine Koenigsberg: Good morning, and welcome to ...

Kymera Therapeutics Inc (KYMR) showcases robust financial health and strategic pipeline advancements amid competitive ...

Q1 2025 Earnings Conference Call May 9, 2025 10:00 AM ETCompany ParticipantsJustine Koenigsberg - Vice President ...

ABCL575 is a novel, half-life extended anti-OX40L monoclonal antibody that is being developed for the treatment of ...

We identify the fat body-derived cytokine, Upd2, in targeting and inducing JAK/STAT signaling in tracheal progenitors to maintain their directional migration. Perturbation of either Upd2 production in ...

However, the cause of fibroblast excessive proliferation and differentiation is not clear. Immune abnormalities may play an important role, with cytokines, chemokines, growth factors, and other ...

CD4 + type 2 helper T (Th2) cells facilitate the adaptive immune response through the secretion of cytokines such as IL-4, IL-5, and IL-13. While the Th2 program is governed by the transcription ...

PITTSBURGH--(BUSINESS WIRE)--CytoAgents Inc., a clinical-stage biotechnology company developing CTO1681 for the prevention and treatment for Cytokine Release Syndrome (CRS), announced the ...